8-K: Spruce Biosciences Implements 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance

Spruce Biosciences, Inc. announced a 1-for-75 reverse stock split, effective August 4, 2025, aimed at meeting Nasdaq's minimum bid price requirement for continued listing.

Summary

• A one-for-seventy-five (1:75) reverse stock split of outstanding common stock was approved by stockholders on July 22, 2025, and subsequently by the Board of Directors on July 23, 2025.
• The reverse stock split will be effective as of August 4, 2025, at 5:00 p.m. Eastern Time.
• Every 75 shares of issued and outstanding common stock will be automatically converted into one share, without any change in par value per share ($0.0001).
• The number of issued and outstanding shares of common stock will be reduced from approximately 42.2 million shares to approximately 0.6 million shares.
• Proportionate adjustments will be made to shares available under equity incentive plans, employee stock purchase plans, and shares issuable upon exercise of warrants, stock options, and restricted stock units, with corresponding increases in exercise prices.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment in lieu thereof.
• The company's common stock is scheduled to begin trading on the OTC Pink Marketplace on a split-adjusted basis on August 5, 2025, under the existing ticker symbol SPRB.
• The company aims to resume trading on the Nasdaq Capital Market if it remains in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for 20 consecutive trading days following the effective date.
• The new CUSIP number for the common stock following the Reverse Stock Split is 85209E 208.
• Stockholders elected Percival Baretto-Ko and Bali Muralidhar, M.D., Ph.D. as Class II Directors to serve until the 2028 Annual Meeting.
• Stockholders ratified the selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 3

Explanation: A reverse stock split, particularly one with a 1:75 ratio, is generally viewed negatively as it often signals a company's struggle with a low stock price and potential delisting. While it's a necessary step to maintain exchange compliance, it doesn't fundamentally improve the company's business operations or financial health, and can sometimes be followed by further price declines.

Positives

• The reverse stock split is a proactive measure to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining listing on a major exchange.
• Stockholder approval of the reverse stock split proposal indicates alignment between management and shareholders on this strategic action.
• Maintaining a Nasdaq listing can enhance the company's visibility, liquidity, and appeal to institutional investors.

Negatives

• The necessity of a 1-for-75 reverse stock split indicates a significantly depressed stock price, often signaling underlying performance issues or a lack of investor confidence.
• There is no guarantee that the company will successfully regain or maintain its Nasdaq listing, which could lead to continued trading on the less liquid OTC Pink Marketplace.
• Reverse stock splits can sometimes be followed by further stock price declines, as they do not address fundamental business challenges.

Risks

• Failure to meet Nasdaq's minimum bid price requirement for 20 consecutive trading days following the effective date could result in the company not resuming trading on the Nasdaq Capital Market.
• The stock price may not sustain the necessary level post-split, potentially leading to future compliance issues or further delisting concerns.
• Continued stock price volatility or decline post-split could erode shareholder value despite the reduced share count.

Future Outlook

The company anticipates resuming trading on the Nasdaq Capital Market provided it remains in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for 20 consecutive trading days following the effective date of the reverse stock split.

Management Comments

• Spruce Biosciences, Inc. announced it will implement a 1-for-75 reverse stock split of its issued and outstanding shares of common stock, effective at 5:00 p.m. Eastern Time on August 4, 2025.

Industry Context

Reverse stock splits are a common strategy for companies, particularly in the biotechnology sector, that have experienced significant stock price declines, often falling below the minimum bid price requirements of major exchanges like Nasdaq. This action is typically a defensive measure to maintain listing, which is critical for liquidity, attracting institutional investment, and maintaining perceived credibility. Many small-cap biotechs face this challenge due to the long, costly, and uncertain nature of drug development and clinical trials.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action employed by companies, especially in the biotech industry, when their share price falls below exchange listing requirements. This is a common occurrence for development-stage companies with no commercial products.
• The 1-for-75 ratio is a substantial consolidation, indicating a significant need to increase the per-share price to meet Nasdaq's minimum bid requirement. While ratios vary, higher ratios like this are typically seen in companies that have experienced prolonged and severe stock price depreciation.
• The objective of regaining Nasdaq listing is a standard and critical goal, as Nasdaq offers greater visibility, analyst coverage, and liquidity compared to the OTC Pink Marketplace, which is generally associated with higher risk and less institutional interest.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares decrease by a factor of 75, but their proportionate ownership interest in the company will remain unchanged, except for those receiving cash for fractional shares. The action aims to preserve Nasdaq listing, which could benefit liquidity and investor confidence.
• Employees holding stock options or restricted stock units will have their share counts adjusted proportionately, with corresponding increases in exercise prices, maintaining the intrinsic value of their holdings.

Next Steps

• Common stock is scheduled to begin trading on the OTC Pink Marketplace on a split-adjusted basis when the market opens on August 5, 2025.
• The company will monitor its stock price to meet the Nasdaq minimum bid price requirement for 20 consecutive trading days to resume trading on the Nasdaq Capital Market.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to address Nasdaq listing compliance issues stemming from a low share price. While it's a positive step towards maintaining market visibility and liquidity, it does not inherently improve the company's operational fundamentals or financial performance. Investors should maintain their current positions to observe if the company successfully regains and sustains Nasdaq compliance and demonstrates progress in its biopharmaceutical pipeline, which would be the true drivers of long-term value. Without further positive operational news, a 'buy' recommendation is not justified, but a 'sell' might be too aggressive if the company's underlying assets still hold potential.

Keywords

Spruce Biosciences, SPRB, Reverse Stock Split, Nasdaq Compliance, Biopharmaceutical, Corporate Action, Stock Market, Delisting, Equity Incentive Plans, Corporate Governance